USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARBOR VITA CORPORATION
Address:
6611 Dumbarton Circle
FREMONT, CA
Phone:
N/A
URL:
N/A
EIN:
177048381
DUNS:
37387904
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,581,158.00 8
SBIR Phase II $5,380,495.00 4

Award List:

A NOVEL FAMILY OF LYMPHOCYTE ADHESION MOLECULES

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$198,318.00
Agency:
HHS
Principal Investigator:
Peter S. Lu
Abstract:
DESCRIPTION: T cell activation is controlled by a highly organized multi-molecular structure at the T cell-antigen presenting cell interface. This structure has recently been termed an "immunological synapse." In an effort to find novel molecules involved in this… More

Prevention and Treatment of Cervical Cancer

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$200,186.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Arbor Vita proposes to validate the interactions of oncogenic E6 variants with a specific cellular protein family as a target for therapeutic intervention in Human papilloma virus (HPV) infection and cervical cancer. Oncogenic variants of HPVs have been… More

A Novel Diagnostic for Oncogenic HPV

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$189,568.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Arbor Vita proposes to detect and quantify oncogenic E6 proteins as a diagnostic test for Human Papilloma Virus (HPV) infection and cervical cancer. Oncogenic variants of HPVs have been correlated with cervical cancer at a frequency of 99.7%. Accumulated data… More

A Novel Drug To Reduce Neronal Damage Following Stroke

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$197,624.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Arbor Vita proposes to determine the selectivity profiles of NMDA Receptors for PDZ domains and to identify selective inhibitors for use in reducing neuronal damage following a stroke. Stroke is a severe disorder that affects about 600,000 people a year in the… More

A Novel Diagnostic Assay for Oncogenic Human Papillomaviruses

Award Year / Program / Phase:
2006 / SBIR / Phase II
Award Amount:
$875,698.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Arbor Vita Corporation (AVC) has developed a novel cervical cancer diagnostic based on an understanding of the biology of human papillomavirus (HPV). HPV infection is one of the most common sexually transmitted diseases with an estimated 5.5 million new… More

Rapid Strip Test for Cervical Cancer via HPV-E6 Detection

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$597,497.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cervical cancer is a global health problem that continues to result in over 200,000 deaths a year and has one of the worst survival rates following diagnosis. Early detection of cervical abnormalities using the Pap smear has significantly reduced the number of… More

Development of an E6 based Rapid Strip Test Commercial Prototype for Cervical Can

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,000,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cervical cancer is a global health problem that continues to result in over 250,000 deaths a year, with 80% occurring in developing countries. Early detection of cervical abnormalities using the Pap smear has proven suc cessful in reducing the number of deaths in… More

Translation of a Novel Stroke Drug Administration

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$1,543,797.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Stroke is a major cause of morbidity in the United States, affecting over 600,000 people annually. The only therapeutics currently available for the treatment of stroke are thrombolytic agents such as tPA, which have li mited efficacy and are inappropriate for… More

PDZ-targeted Therapeutics for Cervical Cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$208,622.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Oncogenic variants of human papilloma virus (HPV) have been correlated with cervical cancer at a frequency of gt 99%, and also cause penile, anal and head and neck cancers. We have recently determined that all oncogeni c E6 proteins bind to the first PDZ domain… More

E6 Oncoprotein Based Rapid Test for Anal Neoplasia

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$692,354.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The prevalence of anal pre-cancer and cancer have substantially increased during the past decades. This is especially true for HIV-positive men and women, and for men who have sex with men (MSM); an increase has been al so seen, however, in men and women in the… More

Development of an HPV-E6 Cervical Neoplasia Test for Use in Centralized Diagnosti

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$296,989.00
Agency:
HHS
Principal Investigator:
Aida A. Fantaye – 408-585-3938
Abstract:
DESCRIPTION (provided by applicant): Cervical cancer is the leading cause of cancer-related death in women. It causes over 250,000 death world-wide / year, with 80% occurring in countries without systematic cervical neoplasia screening programs5. High risk Human Papillomavirus (HPV) infection is… More

Commercialization of the OncoE6TM Cervical Test for detection of HPV induced mali

Award Year / Program / Phase:
2013 / SBIR / Phase II
Award Amount:
$961,000.00
Agency:
HHS
Principal Investigator:
Johannes G. Schweizer – 408-585-3926
Abstract:
DESCRIPTION (provided by applicant): Commercialization of the OncoE6TM Cervical Test for detection of HPV induced malignancy Cervical cancer is a major cause of the cancer-related mortality of women and causes over 250,000 deaths per year worldwide, with about 80% of total mortality occurring in… More